---
title: "Understanding the Market | GIANT BIOGENE falls over 4% against the trend, hitting a new low in 9 months, as the market focuses on the potential recovery of sales during Double Eleven"
description: "GIANT BIOGENE fell over 4% against the trend, hitting a low of HKD 47.92, a new low since January this year. As of the time of writing, it has dropped 4.09%, trading at HKD 48.1, with a transaction vo"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261173356.md"
published_at: "2025-10-15T04:01:03.000Z"
---

# Understanding the Market | GIANT BIOGENE falls over 4% against the trend, hitting a new low in 9 months, as the market focuses on the potential recovery of sales during Double Eleven

> GIANT BIOGENE fell over 4% against the trend, hitting a low of HKD 47.92, a new low since January this year. As of the time of writing, it has dropped 4.09%, trading at HKD 48.1, with a transaction volume of HKD 457 million. On the news front, the curtain for the 2025 "Double 11" shopping festival has quietly been raised. According to Zheshang Securities, the Q3 off-season for cosmetics is relatively weak. Data from Chan Mama shows that the growth rate of some key brands on the Douyin channel weakened in Q3, with GIANT BIOGENE's Q3 Douyin GMV increasing by 15% year-on-year, of which KeFuMei increased by 5% year-on-year and KeLiJin increased by 78% year-on-year. GIANT BIOGENE will focus on the Double 11 efforts in the second half of the year. It is worth noting that the restructuring of KeFuMei's collagen has recently stirred up waves again. Huaxi Bio stated at the end of September that it has collaborated with several third-party testing institutions, including the National Institute of Metrology, to test relevant products from related companies, with dozens of test results showing that the amount of recombinant collagen in the relevant products did not meet standards. Huaxi Bio stated, "We have submitted dozens of test reports to the National Medical Products Administration."

According to Zhitong Finance APP, GIANT BIOGENE (02367) fell more than 4% against the trend, hitting a low of HKD 47.92, a new low since January this year. As of the time of writing, it has dropped 4.09%, trading at HKD 48.1, with a transaction volume of HKD 457 million.

On the news front, the curtain for the 2025 "Double 11" shopping festival has quietly been raised. According to Zheshang Securities, the Q3 off-season for cosmetics is relatively weak. Data from Chan Mama shows that the growth rate of some key brands on Douyin's channel weakened quarter-on-quarter in Q3, with GIANT BIOGENE's Q3 Douyin GMV increasing by 15% year-on-year, of which Kefu Mei increased by 5% year-on-year, and Keli Jin increased by 78% year-on-year. GIANT BIOGENE is focusing on the "Double 11" efforts in the second half of the year.

It is worth noting that the restructuring of Kefu Mei's collagen has recently stirred up waves again. Huaxi Bio stated at the end of September that it has collaborated with several third-party testing institutions, including the National Institute of Metrology, to conduct tests on related products from relevant companies, with dozens of test results showing that the added amount of recombinant collagen in the related products did not meet standards. Huaxi Bio stated, "Dozens of test reports have been submitted to the National Medical Products Administration."

### Related Stocks

- [02367.HK - GIANT BIOGENE](https://longbridge.com/en/quote/02367.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 早盘趋势｜巨子生物多头信心松动，关键支撑岌岌可危？ | 1 月 27 日，巨子生物（2367.HK）盘中弱势震荡，盘面反复探底，多次试探 28 元整数关口支撑未果。全天资金持续流出，绿盘成交占比高，显示多头信心逐步松动，主力持仓筹码开始松懈。 生物科技板块过去一周受地方政策分歧影响，持续表现低迷 | [Link](https://longbridge.com/en/news/273815223.md) |
| 巨子生物获得中国批准推出全球首个胶原蛋白 - 透明质酸皮肤植入物 | 巨子生物控股有限公司已获得中国对其重组 I 型α1 亚型胶原蛋白和透明质酸复合溶液的批准，这是首个用于改善面颊光滑度的皮内注射产品。该产品增强了公司的胶原蛋白产品组合，并预计将为皮肤再生创造新的市场机会。目前，分析师对巨子生物股票（HK:2 | [Link](https://longbridge.com/en/news/272675579.md) |
| 1750 亿美元 “关税退款”！对美股是 “财政刺激”，对美债是 “增加债务”，对金银是 “不确定性重来” | 1750 亿美元潜在退款短期利好美股，零售消费股受益，但该裁决导致关税收入缺失，未来十年或为美债增加超 2 万亿美元负担。特朗普表态将通过其他途径重征关税，政策不确定性加剧，黄金周五暴涨 2% 突破 5100 美元，白银涨 8%，避险情绪升 | [Link](https://longbridge.com/en/news/276502057.md) |
| 谁在春晚开始前打广告 | 今年春晚广告中，酒类品牌依旧占据重要位置，古井贡酒、五粮液、汾酒等频繁出现，显示出其在市场中的强势地位。广告时段的竞争激烈，尤其是 20 点前的广告位，成为品牌争夺的焦点。与此同时，智能家居等新兴产品也逐渐被纳入广告阵列，反映出消费者对生活 | [Link](https://longbridge.com/en/news/276085360.md) |
| 高院否决是” 一回事”，美国退税是” 另一回事” | 在等待美国高院裁决期间，超过 1500 家企业已提起诉讼争取退税，但资格认定、证明文件等关键问题仍未明确。专家称若无美国国会介入实现自动退税，流程可能耗时数年。零售业虽获短期利好，但贸易不确定性持续。 | [Link](https://longbridge.com/en/news/276499113.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.